128 related articles for article (PubMed ID: 35843475)
1. Cold atmospheric plasma enhances doxorubicin selectivity in metastasic bone cancer.
Mateu-Sanz M; Ginebra MP; Tornín J; Canal C
Free Radic Biol Med; 2022 Aug; 189():32-41. PubMed ID: 35843475
[TBL] [Abstract][Full Text] [Related]
2. Cold plasma-treated medium preferentially eliminates doxorubicin-resistant osteosarcoma cells.
Tornín J; Gallego B; Rey V; Murillo D; Huergo C; Rodríguez A; Canal C; Rodríguez R
Free Radic Biol Med; 2023 Nov; 209(Pt 1):127-134. PubMed ID: 37844652
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of cold atmospheric pressure plasma and free or liposomal doxorubicin on melanoma cells.
Pefani-Antimisiari K; Athanasopoulos DK; Marazioti A; Sklias K; Rodi M; de Lastic AL; Mouzaki A; Svarnas P; Antimisiaris SG
Sci Rep; 2021 Jul; 11(1):14788. PubMed ID: 34285268
[TBL] [Abstract][Full Text] [Related]
4. Cold plasma and inhibition of STAT3 selectively target tumorigenicity in osteosarcoma.
Tornín J; Mateu-Sanz M; Rey V; Murillo D; Huergo C; Gallego B; Rodríguez A; Rodríguez R; Canal C
Redox Biol; 2023 Jun; 62():102685. PubMed ID: 36989573
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
[TBL] [Abstract][Full Text] [Related]
6. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
Qiu R; Sun D; Bai Y; Li J; Wang L
Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
[TBL] [Abstract][Full Text] [Related]
7. Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells.
Feng T; Qiao G; Feng L; Qi W; Huang Y; Yao Y; Shen Z
Mol Med Rep; 2014 Dec; 10(6):2985-92. PubMed ID: 25310700
[TBL] [Abstract][Full Text] [Related]
8. Encapsulation of doxorubicin prodrug in heat-triggered liposomes overcomes off-target activation for advanced prostate cancer therapy.
Pereira S; Ma G; Na L; Hudoklin S; Kreft ME; Kostevsek N; Al-Jamal WT
Acta Biomater; 2022 Mar; 140():530-546. PubMed ID: 34954416
[TBL] [Abstract][Full Text] [Related]
9. Effects of cold atmospheric-pressure plasma in combination with doxorubicin drug against breast cancer cells in vitro and invivo.
Dezhpour A; Ghafouri H; Jafari S; Nilkar M
Free Radic Biol Med; 2023 Nov; 209(Pt 2):202-210. PubMed ID: 37890599
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
Li Y; Hou H; Zhang P; Zhang Z
Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
[TBL] [Abstract][Full Text] [Related]
11. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
[TBL] [Abstract][Full Text] [Related]
12. A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro.
Wei H; Chen J; Wang S; Fu F; Zhu X; Wu C; Liu Z; Zhong G; Lin J
Int J Nanomedicine; 2019; 14():8603-8610. PubMed ID: 31802872
[TBL] [Abstract][Full Text] [Related]
13. Cardiomyocyte apoptosis vs autophagy with prolonged doxorubicin treatment: comparison with osteosarcoma cells.
Tacar O; Indumathy S; Tan ML; Baindur-Hudson S; Friedhuber AM; Dass CR
J Pharm Pharmacol; 2015 Feb; 67(2):231-43. PubMed ID: 25208656
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumour activity of low molecular weight heparin doxorubicin nanoparticles for histone H1 high-expressive prostate cancer PC-3M cells.
Zhang S; Li ZT; Liu M; Wang JR; Xu MQ; Li ZY; Duan XC; Hao YL; Zheng XC; Li H; Feng ZH; Zhang X
J Control Release; 2019 Feb; 295():102-117. PubMed ID: 30582952
[TBL] [Abstract][Full Text] [Related]
15. The effect of ciprofloxacin on doxorubicin cytotoxic activity in the acquired resistance to doxorubicin in DU145 prostate carcinoma cells.
Davary Avareshk A; Jalal R; Gholami J
Med Oncol; 2022 Sep; 39(12):194. PubMed ID: 36071289
[TBL] [Abstract][Full Text] [Related]
16. Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model.
Tan ML; Friedhuber AM; Dass CR
J Pharm Pharmacol; 2013 Jan; 65(1):35-43. PubMed ID: 23215686
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Cold Atmospheric Plasma Devices' Efficacy on Osteosarcoma and Fibroblastic
Gümbel D; Suchy B; Wien L; Gelbrich N; Napp M; Kramer A; Ekkernkamp A; Daeschlein G; Stope MB
Anticancer Res; 2017 Oct; 37(10):5407-5414. PubMed ID: 28982850
[TBL] [Abstract][Full Text] [Related]
18. Basic fibroblast growth factor promotes doxorubicin resistance in chondrosarcoma cells by affecting XRCC5 expression.
Hsieh MJ; Huang C; Lin CC; Tang CH; Lin CY; Lee IN; Huang HC; Chen JC
Mol Carcinog; 2020 Mar; 59(3):293-303. PubMed ID: 31916307
[TBL] [Abstract][Full Text] [Related]
19. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22.
Zhu K; Yuan Y; Wen J; Chen D; Zhu W; Ouyang Z; Wang W
Aging (Albany NY); 2020 Apr; 12(8):6644-6666. PubMed ID: 32302291
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet.
Nobuto H; Sugita T; Kubo T; Shimose S; Yasunaga Y; Murakami T; Ochi M
Int J Cancer; 2004 Apr; 109(4):627-35. PubMed ID: 14991586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
